Novo Nordisk (NVO) said Friday that its experimental obesity therapy, CagriSema, met the primary endpoint in a phase 3 trial, showing superior weight loss compared to a placebo, but the results fell short of its expectations.
The company said at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, but that was below the company's expectations for the drug to deliver 25% weight loss.
The weight loss observed from CagriSema did, however, surpass the reductions of 11.8% for cagrilintide 2.4 mg, 16.1% for semaglutide 2.4 mg, and 2.3% for placebo.
The study showed that 57.3% of patients treated with CagriSema were on the highest dose compared to 82.5% with cagrilintide 2.4 mg and 70.2% with semaglutide 2.4 mg, as the trial was flexible, allowing patients to modify their dosing.
Additionally, 40.4% of CagriSema patients lost 25% or more of their body weight, compared to just 6% with cagrilintide, 16.2% with semaglutide, and 0.9% with placebo.
Novo Nordisk said it expects results from its second phase 3 trial in adults with type 2 diabetes and obesity or overweight to be available in H1 2025.
Shares of the company fell 28% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.